First Citizens Bank & Trust CO Catalent, Inc. Transaction History

First Citizens Bank & Trust CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 22, 2024	SELL	$32.18 - $46.57 $624,485 - $903,737	-19,406 Reduced 28.67%	48,282 $2.17 Million
Q3 2023 Oct 30, 2023	BUY	$44.2 - $50.2 $576,456 - $654,708	13,042 Added 23.87%	67,688 $3.08 Million
Q2 2023 Aug 15, 2023	SELL	$31.86 - $67.26 $117,149 - $247,315	-3,677 Reduced 6.3%	54,646 $2.37 Million
Q1 2023 May 11, 2023	BUY	$45.44 - $74.26 $2.65 Million - $4.33 Million	58,323 New	58,323 $3.83 Million

511

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of First Citizens Bank & Trust CO, based on Form 13F filings with the SEC.

Stay updated on First Citizens Bank & Trust CO with notifications on news.